Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于控股股东部分股权质押的公告
Regulatory Filings Classification · 91% confidence The document is an official announcement (“公告”) detailing the pledge of shares by the controlling shareholder. It does not present financial results, governance changes, M&A, or dividends, nor is it a formal financial report. It fits none of the specialized categories (e.g., share issue, buyback) and is a standard regulatory disclosure about share pledges. Therefore it falls under the fallback category Regulatory Filings (RNS).
2026-05-27 Chinese
第四届董事会第八次会议决议公告
Board/Management Information Classification · 90% confidence The document is an announcement of the Fourth Board’s 8th meeting resolutions, detailing board nominations of an independent director, revisions to executive compensation rules, and scheduling of an extraordinary shareholders’ meeting. This is a Board/Management Information release rather than a shareholder vote result, financial report, or other category.
2026-05-26 Chinese
独立董事提名人声明与承诺（白礼西）
Board/Management Information Classification · 85% confidence The document is an independent director nomination statement and commitment by the company’s board, detailing the candidate’s compliance with legal and exchange requirements. It is not a financial or audit report but pertains to changes in the board of directors (nomination of a new independent director). This fits the Board/Management Information category.
2026-05-26 Chinese
关于补选独立董事的公告
Board/Management Information Classification · 86% confidence The document is an official announcement by Chongqing Huashen Pharmaceutical regarding the resignation of an existing independent director and the nomination/election of a new independent director to the board. It details board composition changes, committee appointments, and related qualifications. This fits the definition of a Board/Management Information filing (MANG).
2026-05-26 Chinese
关于召开2026年第二次临时股东会通知的公告
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice to shareholders of Chongqing Hansen Pharmaceutical Co., Ltd. convening the 2026 second extraordinary general meeting. It details the meeting date, agenda items, voting procedures, proxy forms, attachments (proxy authorization, registration forms, network voting instructions) and solicits shareholder votes. It is not the outcome of voting (DVA), nor an annual or interim financial report, but rather the proxy solicitation/information statement for a shareholder meeting.
2026-05-26 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 91% confidence The document is an implementation announcement of the company’s 2025 annual equity distribution (cash dividend) scheme, specifying dividend per share, record date, ex-dividend date, tax treatment, and payment methods. It does not present full financial statements or broader report content but solely details dividend amounts and distribution logistics. This matches the definition of a ‚Notice of Dividend Amount‘ filing.
2026-05-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.